Video

BCAN Think Tank 2023 VL

Search

Bladder Cancer's Dual Approach: How Radiation and Immunotherapy Are Changing the Game, Discussion - Brian Baumann, Parminder Singh, & Scott Delacroix Details In a multi-faceted discussion among medical experts, the focus is on optimizing bladder cancer treatment strategies, particularly the interplay between radiation, immunotherapy, and surgical interventions like TURBT. Dr. Brian Baumann and others emphasize the importance of tailoring treatments to patient risk factors and discuss preliminary data from trials like the SWOG/NRG, indicating tolerabili...
Radiation Therapy for Local Recurrence and for Oligometastatic Bladder Cancer - Brian Baumann Details In his talk, Brian Baumann explores radiation therapy for local recurrence and oligometastatic bladder cancer, emphasizing the importance of adjuvant radiation in preventing local recurrence, particularly in patients with locally advanced T3 and T4 disease or node-positive cases. He reviews key studies supporting adjuvant radiotherapy and highlights that modern techniques like IMRT are well-tolera...
Unraveling the Complexities of Treating Node Positive Bladder Cancer Presentation - Monika Joshi Details At the 2023 Bladder Cancer Advocacy Network (BCAN) Think Tank Monika Joshi delivers an enlightening talk on the subject of node-positive non-metastatic bladder cancer, a new area that only started to be defined in 2017. She covers the emphasis on the recent classification of this type of bladder cancer, the EA8185 cooperative group study, and the challenges and considerations regarding lymph node...
A Clinical Exploration of Radiation and Trimodality Therapy in Bladder Cancer Presentation - Scott Delacroix Details At the 2023 Bladder Cancer Advocacy Network (BCAN) Think Tank meeting Scott Delacroix elucidates on the role of radiation therapy in treating non-muscle invasive bladder cancer, focusing on its potential and his personal experiences with trimodality therapy for muscle-invasive bladder cancer. He discusses a Single Arm Phase 2 study (RTOG 0926) and its outcomes, and presents data on combining immun...